Schedule III

The DEA has initiated an administrative hearing to reclassify marijuana as a Schedule III substance under the Controlled Substances Act, which would facilitate research but not alter criminal penalties or mandatory minimums.

Tennessee’s near-total THCa ban, effective Wednesday, prohibits smokable hemp products with 0.3% or higher THCa concentration while allowing low-potency edibles and vapes. The law closes a 2022 loophole that allowed THCa products, impacting retailers and reducing projected tax revenue. Medical THC remains illegal, though lawmakers may propose medical use next year following federal reclassification.

The Drug Enforcement Administration is considering rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act, which would classify cannabis products as having accepted medical use. The article argues this move lacks scientific evidence and criticizes policymakers for prioritizing politics over science.

Trulieve Cannabis Co., Florida's largest marijuana provider, has been approved for listing on the New York Stock Exchange (NYSE), set to become the first U.S. cannabis company on the NYSE. The approval followed federal reclassification of medical marijuana to Schedule III, enabling DEA registration for state-licensed companies.

High-potency cannabis products, including concentrates with over 80% THC, are fueling state debates over mental health risks like psychosis and addiction. Some states have introduced legislation to limit THC potency, while others resist due to industry opposition and uncertain research. A Connecticut mother's son developed cannabis use disorder after using high-THC cannabis to manage anxiety, leading to severe mental health decline.

The U.S. Department of Justice rescheduled medical marijuana from Schedule I to III, allowing federal tax benefits and research opportunities, but recreational cannabis remains Schedule I. States with medical or recreational programs await further federal guidance, with some, like Nevada and California, adjusting regulations to align with the rescheduling while maintaining existing state laws.

The U.S. Department of Justice rescheduled medical marijuana from Schedule I to III, allowing federal tax benefits and research opportunities, but federal and state cannabis policies remain divided. States like Nevada and California have acknowledged the change but emphasize their laws remain unchanged, awaiting further federal guidance.

The U.S. Department of Justice rescheduled medical marijuana from Schedule I to Schedule III, allowing federal tax benefits and research opportunities, but recreational cannabis remains Schedule I. States with medical or recreational programs are navigating the shift while awaiting further federal guidance, as the DEA prepares to consider broader marijuana de-scheduling.

The Trump administration partially rescheduled cannabis, moving state medical cannabis products and FDA-approved cannabis from Schedule I to Schedule III. Acting Attorney General Todd Blanche signed the order, but experts criticize the move for complicating an already complex regulatory process.

Marijuana has been reclassified from Schedule I to Schedule III under a new order, aligning it with substances like ketamine and testosterone. This change affects state-licensed medical marijuana by categorizing it alongside certain prescription medications.

The Trump administration, led by Acting Attorney General Todd Blanche, has reclassified medical marijuana from Schedule I to Schedule III, aligning it with substances like ketamine and anabolic steroids. This regulatory change aims to ease restrictions on certain marijuana categories.

The Trump administration reclassified cannabis from Schedule I to Schedule III under the Controlled Substances Act, signaling a shift in federal drug policy. This change, led by the U.S. Drug Enforcement Administration (DEA), aims to facilitate medical research and reduce legal barriers for cannabis-related businesses.

President Donald Trump's acting attorney general reclassified state-licensed medical marijuana from Schedule I to Schedule III, easing federal regulations, providing tax breaks, and facilitating research. The move supports existing state medical marijuana programs and sets a hearing for broader reclassification.

The Trump administration has reclassified marijuana from schedule I to schedule III under the Controlled Substances Act, aligning it with drugs like ketamine and steroids. Previously, marijuana was classified alongside heroin, LSD, and synthetic opioids. The change follows an executive order signed by Donald Trump over four months ago.